EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity

Zoë Parker Cates, Antonio Facciuolo, Erin Scruten, Anthony Kusalik, Scott Napper iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0330741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Zoë Parker Cates und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. Hauptthemen laut MEDLINE: Peptides, Vaccine Development, COVID-19 Vaccines. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccines of enhanced range of protection could help to control newly emerging infectious diseases while providing greater resilience to any subsequent variants. Such “universal vaccines” are an idealized, but unrealized, goal that may benefit from unbiased, high-throughput approaches that define antibody cross-reactivity to enable rational selection of cross-protective epitopes. The priority of this investigation is to establish a pipeline for the identification and preliminary characterization of epitopes with enhanced cross-reactivity. A peptide immunoarray representing the proteomes of SARS-CoV, SARS-CoV-II, and MERS-CoV was applied to characterize spike glycoprotein-specific antibody populations within convalescence serum of SARS-CoV-II infected ferrets. Through two alternate bioinformatic approaches, twenty candidate epitopes were identified and translated into vaccines. Epitopes inducing antibodies with cross-reactivity across naturally occurring versions of spike glycoprotein, including SARS-CoV-II Delta and Omicron variants, as well as antigenically distant SARS-CoV and MERS-CoV, were identified. Working from the assumption that cross-reactivity is prerequisite for cross-protection, this highlights the opportunity and mechanisms by which immunoarrays, coupled with in vitro screening assays, can enable rational selection of epitopes with enhanced potential for cross-protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidesVaccine DevelopmentCOVID-19 VaccinesCross ReactionsAnimalsFerretsSpike Glycoprotein, CoronavirusAntibodies, ViralSARS-CoV-2EpitopesCOVID-19HumansMiddle East Respiratory Syndrome CoronavirusSevere acute respiratory syndrome-related coronavirus

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralEpitopesPeptidesCOVID-19 Vaccinesspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Computer Science, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

ORCID-Profile: Scott Napper

Zitieren

APA

Cates, Z. P., Facciuolo, A., Scruten, E., Kusalik, A., & Napper, S. (2025). Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity. PLOS One. https://doi.org/10.1371/journal.pone.0330741

Vancouver

Cates ZP, Facciuolo A, Scruten E, Kusalik A, Napper S. Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity. PLOS One. 2025. doi:10.1371/journal.pone.0330741

BibTeX
@article{Cates2025,
  author = {Cates, Zoë Parker and Facciuolo, Antonio and Scruten, Erin and Kusalik, Anthony and Napper, Scott},
  title = {Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0330741}
}
Kostenlos starten →